ResearcherInstitut Paoli-CalmettesNo recent work listed
Laurence Moureau-Zabotto
Matched on ORCID iD 0000-0002-0341-1812; OpenAlex author ID A5040339716. Sources: ClinicalTrials.gov.
Their work
- Papers
- 6
- Trials
- 1
- Grants
- 0
- Labs led
- 0
- Collaborators
- 13
2003: 1 trial · 2004: none · 2005: none · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: none · 2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers
Papers 6
- Borderline or locally advanced pancreatic adenocarcinoma: A single center experience on the FOLFIRINOX induction regimen. Co-author DOI 10.1016/j.ejso.2020.02.037↗
- Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: a prospective cohort study. Co-author DOI 10.1186/s12885-020-6690-1↗
- Effect of clinical status on survival in patients with borderline or locally advanced pancreatic adenocarcinoma. Co-author DOI 10.1186/s12957-019-1637-1↗
- Patients with resectable pancreatic adenocarcinoma: A 15-years single tertiary cancer center study of laparotomy findings, treatments and outcomes. Co-author DOI 10.1016/j.suronc.2018.07.014↗
- Treatment of Pancreatic Adenocarcinoma in Elderly Patients over 75 Years of Age: A Retrospective Series of 129 Patients. Co-author DOI 10.1007/s12029-015-9774-4↗
- BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic … Co-author DOI 10.1093/annonc/mds135↗
Trials 1
Closest collaborators
The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Olivıer Turrini · 6 shared papers, 2012–2020 · strength 0.49
- Paper Borderline or locally advanced pancreatic adenocarcinoma: A single center experience on the FOLFIRINOX induction regime… DOI 10.1016/j.ejso.2020.02.037↗
- Paper Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: a pr… DOI 10.1186/s12885-020-6690-1↗
- Paper Patients with resectable pancreatic adenocarcinoma: A 15-years single tertiary cancer center study of laparotomy findin… DOI 10.1016/j.suronc.2018.07.014↗
- Marine Gilabert · 6 shared papers, 2012–2020 · strength 0.49
- Paper Borderline or locally advanced pancreatic adenocarcinoma: A single center experience on the FOLFIRINOX induction regime… DOI 10.1016/j.ejso.2020.02.037↗
- Paper Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: a pr… DOI 10.1186/s12885-020-6690-1↗
- Paper Patients with resectable pancreatic adenocarcinoma: A 15-years single tertiary cancer center study of laparotomy findin… DOI 10.1016/j.suronc.2018.07.014↗
- Jean‐Robert Delpéro · 5 shared papers, 2012–2020 · strength 0.43
- Paper Borderline or locally advanced pancreatic adenocarcinoma: A single center experience on the FOLFIRINOX induction regime… DOI 10.1016/j.ejso.2020.02.037↗
- Paper Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: a pr… DOI 10.1186/s12885-020-6690-1↗
- Paper Patients with resectable pancreatic adenocarcinoma: A 15-years single tertiary cancer center study of laparotomy findin… DOI 10.1016/j.suronc.2018.07.014↗
- Marc F. Giovannini · 5 shared papers, 2012–2020 · strength 0.40
- Paper Borderline or locally advanced pancreatic adenocarcinoma: A single center experience on the FOLFIRINOX induction regime… DOI 10.1016/j.ejso.2020.02.037↗
- Paper Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: a pr… DOI 10.1186/s12885-020-6690-1↗
- Paper Effect of clinical status on survival in patients with borderline or locally advanced pancreatic adenocarcinoma. DOI 10.1186/s12957-019-1637-1↗
- Jonathan Garnier · 3 shared papers, 2019–2020 · strength 0.31
- Paper Borderline or locally advanced pancreatic adenocarcinoma: A single center experience on the FOLFIRINOX induction regime… DOI 10.1016/j.ejso.2020.02.037↗
- Paper Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: a pr… DOI 10.1186/s12885-020-6690-1↗
- Paper Effect of clinical status on survival in patients with borderline or locally advanced pancreatic adenocarcinoma. DOI 10.1186/s12957-019-1637-1↗
- Ugo Marchèse · 3 shared papers, 2019–2020 · strength 0.31
- Paper Borderline or locally advanced pancreatic adenocarcinoma: A single center experience on the FOLFIRINOX induction regime… DOI 10.1016/j.ejso.2020.02.037↗
- Paper Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: a pr… DOI 10.1186/s12885-020-6690-1↗
- Paper Effect of clinical status on survival in patients with borderline or locally advanced pancreatic adenocarcinoma. DOI 10.1186/s12957-019-1637-1↗
- Jean‐Luc Raoul · 3 shared papers, 2012–2018 · strength 0.17
- Paper Patients with resectable pancreatic adenocarcinoma: A 15-years single tertiary cancer center study of laparotomy findin… DOI 10.1016/j.suronc.2018.07.014↗
- Paper Treatment of Pancreatic Adenocarcinoma in Elderly Patients over 75 Years of Age: A Retrospective Series of 129 Patients. DOI 10.1007/s12029-015-9774-4↗
- Paper BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus place… DOI 10.1093/annonc/mds135↗
- Pauline Duconseil · 1 shared paper, 2019 · strength 0.09
- Sandrine Oziel-Taïeb · 1 shared paper, 2016 · strength 0.06
- Frédérique Rousseau · 1 shared paper, 2016 · strength 0.06
- Laëtitia Dahan · 1 shared paper, 2012 · strength 0.02
- Anthony Gonçalvès · 1 shared paper, 2012 · strength 0.02
- Éric François · 1 shared paper, 2012 · strength 0.02
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.